PMEL and melanoma: In phase I trials, gp100 peptides, a melanocyte lineage-specific protein expressed in most melanomas, elicited strong anti-melanoma CD8+ cytotoxic lymphocytes (CTLs) (in 14% of patients) and CD4+ helper T cell effects (in 79% of patients)[5,6].